Raymond James & Associates Sarepta Therapeutics, Inc. Transaction History
Raymond James & Associates
- $161 Billion
- Q3 2024
A detailed history of Raymond James & Associates transactions in Sarepta Therapeutics, Inc. stock. As of the latest transaction made, Raymond James & Associates holds 25,713 shares of SRPT stock, worth $483,661. This represents 0.0% of its overall portfolio holdings.
Number of Shares
25,713
Previous 21,648
18.78%
Holding current value
$483,661
Previous $3.42 Million
6.11%
% of portfolio
0.0%
Previous 0.0%
Shares
30 transactions
Others Institutions Holding SRPT
# of Institutions
406Shares Held
83.7MCall Options Held
5.27MPut Options Held
5.94M-
Vanguard Group Inc Valley Forge, PA10.8MShares$203 Million0.0% of portfolio
-
Black Rock Inc. New York, NY10.3MShares$194 Million0.04% of portfolio
-
State Street Corp Boston, MA5.3MShares$99.8 Million0.0% of portfolio
-
Erste Asset Management Gmb H Vienna, C42.69MShares$50.5 Million0.49% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny2.65MShares$49.8 Million0.07% of portfolio
About Sarepta Therapeutics, Inc.
- Ticker SRPT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 87,567,904
- Market Cap $1.65B
- Description
- Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...